Skip to main content Skip to search Skip to main navigation

FDA: Guidance on Substance-related Nitrosamine Risks

This month the US FDA issued a 28-page new guidance for immediate implementation, Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). It provides drug manufacturers and applicants with a framework for a risk-based safety assessment of NDSRIs that could be present in approved and marketed drug products, as well as products under review by the FDA. Ways to predict the mutagenic and carcinogenic risk of NDSRIs and acceptable intake (AI) limits are outlined.

Nitrosamine drug substance-related impurities (NDSRIs) have been identified in many drug products and also could be present in active pharmaceutical ingredients (APIs). Since the publication of the guidance for industry Control of Nitrosamine Impurities in Human Drugs, the FDA has received reports of NDSRIs, which share structural similarities to the API and are unique to each API. Based on the chemical structure of the API, there is a risk of NDSRIs forming in a substantial number of drug products. This guidance is being implemented immediately and it remains subject to comment.

NDSRIs often lack carcinogenicity and mutagenicity study data from which an AI limit can be determined. This guidance provides a recommended methodology for AI limit determination that uses structural features of NDSRIs to generate a predicted carcinogenic potency categorization and corresponding recommended AI limit that manufacturers and applicants can apply, in the absence of other FDA-recommended AI limits, in their evaluations of approved and marketed drug products as well as products in development or under review by FDA.

The FDA guidance introduces the Carcinogenic Potency Categorization Approach (CPCA) which is based on an assessment of activating or deactivating structural features present in the molecule. Furthermore, enhanced testing conditions for the Ames assay are recommended.

Good to know:
Both approaches were also recommended by the European Medicines Agency (EMA) in the July revision of its Q&A on nitrosamine impurities (we reported). The sections and tables on CPCA in the two documents are almost identical. 

Recommended timeline:

  • The FDA asks manufacturers to assess the NDSRI risks within the next three months and to complete their assessment by 1 November 2023, as part of overall risk management.
  • By 1 August 2025, manufacturers, and applicants should complete the three-step mitigation strategy based on increased awareness of NDSRIs.

Source:

FDA: Guideline on Acceptabel Intake Limits for NDSRIs

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next